Introduction: Paving the way for biomedical HIV prevention interventions in youth

Journal of Acquired Immune Deficiency Syndromes

Volumn 54, Issue SUPPL. 1, 2010, Pages

  Kapogiannis, Bill G ^a   Handelsman, Ed ^b   Ruiz, Monica S ^c   Lee, Sonia ^a  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

adolescents; biomedical prevention research; HIV

Indexed keywords

ADOLESCENT; ADOLESCENT HEALTH; CHILD BEHAVIOR; COMMUNITY PROGRAM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INTERVENTION STUDY; MEDICAL TECHNOLOGY; PREVENTION STUDY; PRIMARY PREVENTION; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; SECONDARY PREVENTION; SEXUAL COUNSELING; SHORT SURVEY;

ADOLESCENT; AGE FACTORS; BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; FEMALE; HIV INFECTIONS; HUMANS; MALE; RISK FACTORS; YOUNG ADULT;

EID: 77954074385     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181e2cf8f     Document Type: Short Survey

References (22)

1. Hall, HI, Song R, Rhodes P, et al. Estimation of HIV incidence in the United States. JAMA. 2008;300:520-529.
2. US Centers for Disease Control and Prevention, Trends in HIV/AIDS diagnoses among men who have sex with men\33 states, 2001-2006. MMWR Morb Mortal Wkly Rep. 2008;57:681-686.
3. Joint United Nations Programme on HIV/AIDS (UNAIDS). Report on the global HIV/AIDS epidemic 2008. Available at: www.unaids.org/en/KnowledgeCentre/ HIVData/GlobalReport/2008/2008-Global-report.asp. Accessed March 29, 2010.
4. Foster C, Waelbrouck A, Peltier A. Adolescents and HIV infection. Curr Opin HIV AIDS. 2007;2:431-436.
5. The Adolescent Medicine Trials Network for HIV/AIDS Interventions. Prevention and Care for Today's Youth. Available at: https://www.atnon-line.org. Accessed March: 28, 2010
6. Chutuape KS, Willard N, Sanchez K, et al. Mobilizing communities around HIV prevention for youth: how three coalitions applied key strategies to bring about structural changes. AIDS Educ Prev. 2010;22: 15-27.
7. Geanuracos CG, Cunningham SD, Weiss G, et al. Use of geographic information systems for planning HIV prevention interventions for high-risk youths. Am J Public Health. 2007;97:1974-1981.
8. Ziff MA, Harper GW, Chutuape KS, et al. Laying the foundation for Connect to Protect: a multi-site community mobilization intervention to reduce HIV/AIDS incidence and prevalence among urban youth. J Urban Health. 2006;83:506-522.
9. Ginsberg G, Hattis D, Sonawane B, et al. Evaluation of child/adult pharmacokinetic differences from a database derived from the therapeutic drug literature. Toxicol Sci. 2002;66:185-200.
10. Hein K. Introduction to the special issue on pharmacokinetics and pharmacodynamics in adolescents. J Adolesc Health. 1994;15:609-611.
11. Kapogiannis BG, Mattison DR. Adolescents in clinical trials. Clin Pharmacol Ther. 2008;84:655-659.
12. FDA. Guidance for industry: development of preventive HIV vaccines for use in pediatric populations 2006. Available at: http://www.fda.gov/ BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/ Vaccines/ucm074819.htm. Accessed March 29, 2010.
13. Singh JA, Karim SS, Karim QA, et al. Enrolling adolescents in research on HIV and other sensitive issues: lessons from South Africa. PLoS Med. 2006;3:e180.
14. Cunningham CK, Rudy BJ, Xu J, et al. Randomized trial to determine safety and immunogenicity of two strategies for hepatitis B vaccination in healthy urban adolescents in the United States. Pediatr Infect Dis J. 2010.
15. Kiser JJ, Fletcher CV, Flynn PM, et al. Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection. Antimicrob Agents Chemother. 2008;52:631-637.
16. Mulligan K, Harris DR, Monte D, et al. Obesity and dyslipidemia in behaviorally HIV-infected young women: Adolescent Trials Network study 021. Clin Infect Dis. 2010;50:106-114.
17. Stanford PD, Monte DA, Briggs FM, et al. Recruitment and retention of adolescent participants in HIV research: findings from the REACH (Reaching for Excellence in Adolescent Care and Health) Project. J Adolesc Health. 2003;32:192-203.
18. Ratner M. Profile: Ian Frazer. Nat Biotechnol. 2007;25:1377.
19. Microbicide Trials Network (MTN). VOICE Study, a major HIV prevention trial for women, is launched in Zimbabwe 2009. Available at: http://www.mtnstopshiv.org/node/1416. Accessed March 29, 2010.
20. Liu AY, Grant RM, Buchbinder SP. Preexposure prophylaxis for HIV: unproven promise and potential pitfalls. JAMA. 2006;296:863-865.
21. Peterson L, Taylor D, Roddy R, et al. Tenofovir disoproxil fumarate for prevention of HIV infection in women: a phase 2, double-blind, randomized, placebo-controlled trial. PLoS Clin Trials. 2007;2:e27.
22. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009;361:2209-2220.